Atopic dermatitis therapeutic - Syntekabio
Latest Information Update: 15 Apr 2024
Price :
$50 *
At a glance
- Originator Syntekabio
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Atopic dermatitis
Most Recent Events
- 22 Dec 2023 Atopic dermatitis therapeutic - Syntekabio is available for licensing as of 22 Dec 2023. https://www.syntekabio.com/eng/sub04_question.php
- 29 Nov 2023 Syntekabio files for patent protection for candidate substance for treatment atopic dermatitis in South Korea
- 05 Jul 2023 Preclinical trials in Atopic dermatitis in South Korea (unspecified route) before July 2023